Cora Kit150 mg+600 mg+400 IU

Cora Kit is indicated for use in the management of osteoporosis, combining a bisphosphonate (ibandronic acid) with calcium (from a coral source) and vitamin D3 to support bone mineral density and reduce fracture risk.

Established / Guideline-Supported Uses

• Treatment of postmenopausal osteoporosis: to increase bone mineral density and reduce the risk of vertebral fractures.
• Prevention of postmenopausal osteoporosis in women at increased risk of bone loss.
• Adjunctive calcium and vitamin D3 supplementation to ensure adequate mineral substrate and correct or prevent deficiency during bisphosphonate therapy, since adequate calcium and vitamin D status is required for bisphosphonates to work properly.

Other Reported/Adjunct Uses

• Use in glucocorticoid-induced osteoporosis and other secondary osteoporosis, as directed by a physician (guideline-supported in select patients, not a primary FDA-approved indication for this fixed combination).
• Use in men with osteoporosis at high fracture risk, under specialist supervision (less strong evidence base than postmenopausal indication).

This is a combination product intended to be used exactly as prescribed; it does not replace individualized medical assessment of fracture risk.

Ibandronic Acid + Coral Calcium + Vitamin D3 is a combination product typically containing:

• Ibandronic Acid (as ibandronate sodium): a nitrogen-containing bisphosphonate, commonly available in strengths such as 150 mg (monthly oral tablet) or 2.5 mg (daily oral tablet).
• Coral Calcium (calcium carbonate derived from fossilized coral): providing elemental calcium, commonly 500-600 mg elemental calcium per dose unit.
• Vitamin D3 (cholecalciferol): commonly 200-400 IU per dose unit, to support calcium absorption and bone mineralization.

Exact strengths vary by manufacturer and product presentation; always check the product label/pack insert for the precise composition of the specific brand dispensed.

Cora Kit is a combination medicine used in the management of osteoporosis. It pairs ibandronic acid, a potent nitrogen-containing bisphosphonate that slows bone breakdown (resorption), with coral-sourced calcium and vitamin D3, which together support normal bone mineralization and help ensure that calcium and vitamin D status does not limit the benefit of bisphosphonate therapy.

Cora Kit is generally prescribed for postmenopausal women, and sometimes other patients, at increased risk of osteoporotic fractures, as part of a broader bone health plan that may also include weight-bearing exercise, fall-prevention measures, and lifestyle modification.

Cora Kit belongs to the therapeutic class of anti-osteoporotic agents: a bisphosphonate (bone resorption inhibitor) combined with a calcium supplement and a vitamin D3 (fat-soluble vitamin) analog used for bone health.

Ibandronic Acid

Ibandronic acid is a nitrogen-containing bisphosphonate that binds strongly to bone mineral (hydroxyapatite) at sites of active bone remodeling. It is selectively taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast cytoskeletal function and inducing osteoclast apoptosis. This reduces bone resorption and bone turnover, leading over time to a net increase in bone mineral density.

After oral administration, absorption of ibandronic acid is low (roughly 0.6%) and is further reduced by food, calcium, and other divalent cations, which is why it must be taken on an empty stomach, separated from calcium intake. It is not metabolized, binds extensively to bone, and the unabsorbed/unbound fraction is excreted mainly via the kidneys.

Coral Calcium and Vitamin D3

Coral calcium provides elemental calcium (as calcium carbonate) required for bone mineralization, neuromuscular function, and normal blood clotting. Vitamin D3 (cholecalciferol) is hydroxylated in the liver and kidney to its active form, which increases intestinal absorption of calcium and phosphate and supports normal bone mineralization, working together with calcium to provide the mineral substrate that bisphosphonate therapy needs to be effective.

Ibandronic Acid + Coral Calcium + Vitamin D3 therefore works through complementary mechanisms: reduced bone resorption from ibandronic acid, and adequate mineral/vitamin substrate from calcium and vitamin D3.

Take the ibandronic acid component of Cora Kit first thing in the morning on an empty stomach, with a full glass of plain water, then remain upright for at least 60 minutes and avoid food, drink, or other medicines during that time. Take the calcium/vitamin D3 component at a separate time of day, generally with food, to maximize calcium absorption and avoid interfering with bisphosphonate absorption. Do not take other oral medicines, including calcium, iron, or antacids, within the 60-minute window after the bisphosphonate dose.

Cora Kit contains components with distinct interaction profiles that should be reviewed together with a physician or pharmacist.

• Calcium, iron, antacids, magnesium, and other multivalent cations: significantly reduce absorption of the ibandronic acid component if taken close together; this is why the calcium/vitamin D3 component of Cora Kit must be taken at a separate time from the bisphosphonate dose (see Dosage and Administration).
• Oral bisphosphonates with NSAIDs or aspirin: may additively increase the risk of gastrointestinal/esophageal irritation.
• Thiazide diuretics: can increase serum calcium and add to the effect of the calcium/vitamin D3 component, raising the risk of hypercalcemia; calcium levels should be monitored if co-administered.
• Digoxin: hypercalcemia arising from excess calcium/vitamin D intake can predispose to digoxin toxicity and arrhythmia; caution and monitoring are advised in patients on digoxin.
• Tetracycline or fluoroquinolone antibiotics, and levothyroxine: calcium can reduce absorption of these drugs; separate dosing by at least 2-4 hours from the calcium/vitamin D3 component.
• Other bisphosphonates or high-dose vitamin D/calcium supplements taken concurrently: avoid duplication, as this increases the risk of hypocalcemia/hypercalcemia imbalance and bisphosphonate-related adverse effects.

Side effects of Cora Kit may relate to either the bisphosphonate or the calcium/vitamin D3 component.

Common

• Upper gastrointestinal discomfort: dyspepsia, heartburn, nausea, abdominal pain
• Constipation or diarrhea
• Musculoskeletal pain: back pain, myalgia, arthralgia
• Headache
• Mild flu-like symptoms (more common with intravenous bisphosphonate forms)

Serious (see Precautions and Warnings for full detail)

• Esophageal irritation, esophagitis, or esophageal ulceration
• Osteonecrosis of the jaw
• Atypical femur fractures with prolonged use
• Hypocalcemia or, less commonly, hypercalcemia/vitamin D toxicity with excess supplementation
• Hypersensitivity reactions, including rare severe skin reactions

Cora Kit is intended for use in postmenopausal osteoporosis and is not indicated for use during pregnancy. Ibandronic acid is incorporated into bone and released slowly over a long period, and its effects on a developing fetus if pregnancy occurs after treatment are not fully known; animal studies with bisphosphonates have shown effects on fetal bone development at high doses. Cora Kit should not be used in women who are or may become pregnant unless a physician determines there is a specific, clearly justified need and no safer alternative exists.

It is not known whether the ibandronic acid component passes into breast milk; use during breastfeeding is not recommended. The calcium and vitamin D3 component may generally be appropriate in usual nutritional doses during pregnancy/lactation, but the combination product as a whole should only be used if clearly needed and only under a physician's guidance, weighing potential benefit against potential risk.

Cora Kit carries several important, well-established warnings, chiefly related to its bisphosphonate component:

• Osteonecrosis of the jaw (ONJ): a rare but serious risk, more common with invasive dental procedures during treatment. A dental examination and appropriate preventive dentistry are recommended before starting therapy in patients with risk factors; maintain good oral hygiene throughout treatment.
• Atypical femur fractures: unusual, low-trauma fractures of the femoral shaft have been reported with long-term bisphosphonate use; new thigh, hip, or groin pain during treatment should be evaluated promptly.
• Esophageal reactions: esophagitis, esophageal ulcers, and esophageal erosions have occurred, particularly if administration instructions are not followed. Patients who cannot comply with dosing instructions (upright posture, full glass of water, waiting period) should not take the oral bisphosphonate component. Report new or worsening difficulty/pain on swallowing, chest pain, or new/worsening heartburn promptly.
• Hypocalcemia: must be corrected before starting the bisphosphonate component; the calcium/vitamin D3 component of Cora Kit is intended to help maintain adequate calcium status during treatment, but calcium levels should still be monitored, especially in patients with disorders of mineral metabolism.
• Hypercalcemia/vitamin D toxicity: avoid excessive supplemental calcium or vitamin D intake beyond what is prescribed, as this can cause hypercalcemia, nausea, confusion, and kidney injury.
• Renal function: use with caution and appropriate monitoring in mild-to-moderate renal impairment; avoid in severe renal impairment.
• Musculoskeletal pain: severe and occasionally incapacitating bone, joint, or muscle pain has been reported with bisphosphonates; discuss with a physician if this occurs.

Overdose of the ibandronic acid component may cause hypocalcemia, hypophosphatemia, upper gastrointestinal irritation (heartburn, esophagitis, ulcer), and, in significant excess, gastric or esophageal injury. Overdose of the calcium/vitamin D3 component may cause symptoms of hypercalcemia such as nausea, vomiting, constipation, confusion, excessive thirst, or irregular heartbeat.

If an overdose of Cora Kit is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. The patient should remain upright and not induce vomiting; milk or antacids containing calcium or magnesium may be given to bind the bisphosphonate while awaiting emergency care, but specific treatment must be directed by a physician in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Cora Kit is commonly used in this population (postmenopausal osteoporosis); no specific dose adjustment is generally required beyond attention to renal function.
• Renal impairment: no adjustment usually needed in mild impairment; caution and monitoring advised in moderate impairment; not recommended in severe impairment (creatinine clearance below 30 mL/min) (see Contraindications).
• Hepatic impairment: no specific dose adjustment is established, as ibandronic acid is not metabolized by the liver; use with general caution.
• Pediatric patients: safety and efficacy of Cora Kit have not been established; not indicated for use in children (see Pediatric Uses).
• Pregnancy and lactation: see Pregnancy and Lactation section.

The duration of Cora Kit therapy should be individualized by the prescribing physician based on fracture risk, bone density response, and tolerability. Bisphosphonate therapy for osteoporosis is often continued for approximately 3-5 years, after which the physician may reassess whether to continue, switch therapy, or consider a temporary treatment break ("drug holiday"), since bisphosphonates remain active in bone for a prolonged period after stopping. The calcium and vitamin D3 component is generally continued long term as part of ongoing bone health maintenance, per physician advice. Do not stop or extend treatment without consulting a physician.

Bisphosphonate (nitrogen-containing); Calcium supplement; Vitamin D3 (cholecalciferol) analog; Anti-osteoporotic combination agent

Ibandronic Acid + Coral Calcium + Vitamin D3 acts through ibandronic acid, which inhibits osteoclast-mediated bone resorption by disrupting the mevalonate pathway in osteoclasts, together with coral-sourced calcium and vitamin D3, which supply the mineral substrate and support intestinal calcium absorption needed for normal bone mineralization (see Pharmacology for full detail).

C

Safety and efficacy of Cora Kit have not been established in children and adolescents. Cora Kit is not indicated for use in pediatric patients; osteoporosis management in this age group requires specialist pediatric evaluation and alternative approaches.